Pituitary最新文献

筛选
英文 中文
Precocious puberty, pandemic and beyond. 性早熟、大流行病及以后。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-26 DOI: 10.1007/s11102-024-01434-8
Guillermo F Alonso
{"title":"Precocious puberty, pandemic and beyond.","authors":"Guillermo F Alonso","doi":"10.1007/s11102-024-01434-8","DOIUrl":"https://doi.org/10.1007/s11102-024-01434-8","url":null,"abstract":"<p><p>WHO declared SARS-COVID19 a pandemic in March 2020. Most governments declared health emergency states and implemented various measures. Since then, changes in the reasons for medical consultations were observed in healthcare institutions. Pediatric endocrinologists perceived an increase in the number of consultations related to early or accelerated CPP during the months following the lockdown that different governments had established. Several papers reported the increment in incidence in Central Precocious Puberty, especially in girls. Reports from different parts of the world highlighted a two to threefold rise in the number of cases of precocious puberty treated in Pediatric Endocrinology Centers. This trend of CPP incidence strongly suggests that changes in habits and the environment in which boys and girls were immersed during the lockdown, have played a significant role in triggering the early onset of the gonadotrophic axis.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141767198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence. 在 COVID 大流行期间,垂体腺瘤患者在垂体卓越中心的表现和治疗效果的变化。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-24 DOI: 10.1007/s11102-024-01435-7
Anthony Tang, Hussein M Abdallah, Yue-Fang Chang, Georgios A Zenonos, Paul A Gardner, Garret W Choby, Eric W Wang, Carl H Snyderman
{"title":"Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence.","authors":"Anthony Tang, Hussein M Abdallah, Yue-Fang Chang, Georgios A Zenonos, Paul A Gardner, Garret W Choby, Eric W Wang, Carl H Snyderman","doi":"10.1007/s11102-024-01435-7","DOIUrl":"https://doi.org/10.1007/s11102-024-01435-7","url":null,"abstract":"<p><strong>Purpose: </strong>The COVID-19 pandemic caused significant disruption to the surgical care of patients. The aim of this study was to analyze the impact of the pandemic on endoscopic endonasal surgery (EES) for patients with a pituitary adenoma.</p><p><strong>Methods: </strong>Patients from 2015 to 2022 that had EES for a pituitary adenoma were included in this study. Patients were separated into pre-COVID (January 2015-March 2020) and COVID (March 2020-September 2022) groups. Univariate analysis was done using chi-square, fisher exact tests, and t-tests to compare groups.</p><p><strong>Results: </strong>This study included 492 patients that had EES for their pituitary adenoma. There were 314 patients in the pre-COVID group and 178 patients in the COVID group. Patients in the COVID group had a higher risk analysis index (RAI) frailty score (15 ± 10 pre-COVID vs. 20 ± 9 COVID, P < 0.001) and a higher American Society of Anesthesiology (ASA) physical status score (3 or 4) (72.0% pre-COVID vs. 81.9% COVID, P = 0.02). There were significantly more macroadenoma cases (87.6% pre-COVID vs. 94.4% COVID, P = 0.02) and extrasellar surgical approaches (45.2% pre-COVID vs. 61.2% COVID, P < 0.001) during COVID. There was no significant difference in length of stay (LOS) and readmission rates between groups.</p><p><strong>Conclusions: </strong>Patients that presented during the pandemic tended to be more frail, have more comorbidities, and require additional extrasellar surgical approaches. Despite changes in clinical presentation and operative management, the LOS and readmission rate remained stable during COVID, supporting the safety of this procedure during the recent pandemic.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants. 临床上使用[18F]氟-乙基-L-酪氨酸 PET 与核磁共振成像共同定位催乳素瘤残余。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-23 DOI: 10.1007/s11102-024-01430-y
Victoria R van Trigt, Leontine E H Bakker, Huangling Lu, Iris C M Pelsma, Marco J T Verstegen, Wouter R van Furth, Lenka M Pereira Arias-Bouda, Nienke R Biermasz
{"title":"Clinical use of [<sup>18</sup>F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.","authors":"Victoria R van Trigt, Leontine E H Bakker, Huangling Lu, Iris C M Pelsma, Marco J T Verstegen, Wouter R van Furth, Lenka M Pereira Arias-Bouda, Nienke R Biermasz","doi":"10.1007/s11102-024-01430-y","DOIUrl":"https://doi.org/10.1007/s11102-024-01430-y","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the utility of [<sup>18</sup>F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([<sup>18</sup>F]FET-PET/MRI<sup>CR</sup>) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning.</p><p><strong>Methods: </strong>Retrospective cohort study of 17 consecutive patients with prolactinoma undergoing [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> between October 2020 and September 2022 for either (1) additional information in case of difficult-to-visualize remnants after prior transsphenoidal surgery (TSS), or pharmacological treatment, or (2) radiological diagnosis in absence of a (clear) adenoma on diagnostic/post-treatment conventional MRI.</p><p><strong>Results: </strong>[<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> identified a lesion in 14/17 patients, yet failed to identify active lesions in 2 patients with negative conventional MRI despite prolactin > 7.5 times upper limit of normal. [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> results were inconclusive in 1 patient due to diffuse tracer uptake 10 weeks post-surgery. [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> was completely concordant with a suspected lesion on conventional MRI in 10/17 patients, and partially concordant in 3/17 patients. New foci were identified in 4/17 patients. The [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> conclusions influenced clinical shared decision-making in 15/17 patients, of whom 7 patients underwent TSS and 8 refrained from TSS. One patient underwent TSS despite negative [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup>, and one patient underwent additional imaging. Intraoperative findings corresponded with [<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> in 5/8 patients, and immunohistochemistry was positive in 5/8 patients. The treatment goal was achieved in 7/8 patients, and remission was achieved in 5/7 patients in whom total resection was considered feasible.</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]FET-PET/MRI<sup>CR</sup> can be of added value in the preoperative decision-making process for selected patients with difficult-to-localize prolactinoma (remnants), or patients lacking a substrate on conventional MRI.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copeptin after pituitary surgery: is it worth measuring? 垂体手术后的 Copeptin:值得测量吗?
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-16 DOI: 10.1007/s11102-024-01418-8
Pietro Maffei, Luigi di Filippo
{"title":"Copeptin after pituitary surgery: is it worth measuring?","authors":"Pietro Maffei, Luigi di Filippo","doi":"10.1007/s11102-024-01418-8","DOIUrl":"https://doi.org/10.1007/s11102-024-01418-8","url":null,"abstract":"","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cushing's disease and bone. 库欣氏病与骨骼
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-15 DOI: 10.1007/s11102-024-01427-7
Aleksandra Zdrojowy-Wełna, Barbara Stachowska, Marek Bolanowski
{"title":"Cushing's disease and bone.","authors":"Aleksandra Zdrojowy-Wełna, Barbara Stachowska, Marek Bolanowski","doi":"10.1007/s11102-024-01427-7","DOIUrl":"https://doi.org/10.1007/s11102-024-01427-7","url":null,"abstract":"<p><p>Bone impairment associated with Cushing's disease (CD) is a complex disorder, mainly involving deterioration of bone quality and resulting in an increased fracture rate, often despite normal bone mineral density. Bone complications are common in patients with CD at the time of diagnosis but may persist even after successful treatment. There is currently no agreement on the optimal diagnostic methods, thresholds for anti-osteoporotic therapy and its timing in CD. In this review, we summarize the current data on the pathophysiology, diagnostic approach and management of bone complications in CD.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent. 无功能性促肾上腺皮质激素垂体瘤的预后:无声并不意味着无症状。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-12 DOI: 10.1007/s11102-024-01428-6
Nicolas Sahakian, Lise Goetz, Romain Appay, Thomas Graillon, Isabelle Raingeard, Cécilia Piazzola, Jean Regis, Frédéric Castinetti, Thierry Brue, Henry Dufour, Thomas Cuny
{"title":"Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent.","authors":"Nicolas Sahakian, Lise Goetz, Romain Appay, Thomas Graillon, Isabelle Raingeard, Cécilia Piazzola, Jean Regis, Frédéric Castinetti, Thierry Brue, Henry Dufour, Thomas Cuny","doi":"10.1007/s11102-024-01428-6","DOIUrl":"https://doi.org/10.1007/s11102-024-01428-6","url":null,"abstract":"<p><strong>Introduction: </strong>Silent corticotroph tumors (siACTH) represent a rare entity of pituitary tumors (PT), usually more aggressive than other PT. Few predictor factors of recurrence in the post-operative period have been proposed until now. This study aimed (1) to evaluate the clinical outcome of siACTH after surgery according to a five-tiered clinicopathological classification (2) to compare siACTH characteristics to ACTH-secreting macroadenomas (macroCD), and silent gonadotropinomas (siLH/FSH).</p><p><strong>Patients and methods: </strong>Between 2008 and 2022, 29 siACTH out of 865 PT cases operated in one tertiary center were included. Clinical, paraclinical, histological, and surgical data were collected and compared to 25 macroCD and 143 siLH/FSH cases, respectively. The tumor grading was established according to both invasion (no = 1; yes = 2) and proliferation (no = a; yes = b). Progression-free survival was estimated using Kaplan-Meier method and log-rank test.</p><p><strong>Results: </strong>We identified 15 (51.7%) grade 1a, 11 (37.9%) grade 2a and 3 (10.3%) grade 2b siACTH with a trend for a 7-fold-time higher risk of progression/recurrence in grade 2b as compared to 1a (p = 0.06). The repartition of tumor grades was similar between the three subgroups, however a 5.7-fold-higher risk of progression was observed in grade 1a siACTH than in grade 1a siLH/FSH (p = 0.02). Compared to siLH/FSH, higher ACTH levels may help to preoperatively identify siACTH.</p><p><strong>Conclusion: </strong>The five-tiered clinicopathological classification contribute to predict the risk of recurrence of operated siACTH tumors. Noteworthy, non-invasive and non-proliferative siACTH exhibit a less favorable outcomes than their siLH/FSH counterparts, which should prompt for a personalized follow up.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) for adult patients with hypothalamic-pituitary disorders. 针对下丘脑-垂体疾病成年患者的新型治疗依从性、满意度和知识问卷(TASK-Q)的开发与验证。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-08 DOI: 10.1007/s11102-024-01425-9
Sofia Llahana, Kevin C J Yuen
{"title":"Development and validation of a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) for adult patients with hypothalamic-pituitary disorders.","authors":"Sofia Llahana, Kevin C J Yuen","doi":"10.1007/s11102-024-01425-9","DOIUrl":"https://doi.org/10.1007/s11102-024-01425-9","url":null,"abstract":"<p><strong>Purpose: </strong>Successful treatment outcomes of adults with hypothalamic-pituitary disorders necessitate the adoption of intricate self-management behaviors, yet current scales for evaluating treatment adherence and satisfaction are inadequate for this patient group. This research introduces a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) developed specifically to identify patients' unmet needs in better assessing and managing these disorders.</p><p><strong>Methods: </strong>The study was conducted in three phases: (1) generating items and testing content validity, (2) refining these items through a pilot study, and (3) a main study evaluating the psychometric properties of the TASK-Q scale among 262 adults in a Pituitary Nurse-led Clinic, with 152 (58%) patients completing the questionnaire.</p><p><strong>Results: </strong>Exploratory factor analysis was used to test the factor structure and construct validity of the TASK-Q, revealing a 22-item scale divided into Satisfaction and Knowledge (17 items) and Adherence (5 items) subscales, and exhibiting high internal consistency (Cronbach's α = 0.90). Significant correlations were identified between satisfaction and knowledge (r = 0.67, p < 0.001), satisfaction and adherence (r = 0.23, p = 0.005), and knowledge and adherence (r = 0.43, p < 0.001). Complex treatment regimens, like daily growth hormone injections and adjusting glucocorticoids during illness, negatively affected adherence (p < 0.001).</p><p><strong>Conclusion: </strong>The TASK-Q is a novel validated scale that can effectively evaluate patients' perspectives on adherence, knowledge and satisfaction. Our findings highlight the significant impact of Advanced Nurse Practitioners in improving patient self-management behaviors, which likely leads to better treatment outcomes for people with hypothalamic-pituitary disorders.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients. 通过核磁共振成像对颞肌和咀嚼肌进行评估,可了解肢端肥大症患者的肌肉质量和品质。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-05 DOI: 10.1007/s11102-024-01422-y
Federico Gatto, Angelo Milioto, Giuliana Corica, Federica Nista, Claudia Campana, Anna Arecco, Lorenzo Mattioli, Lorenzo Belluscio, Bianca Bignotti, Diego Ferone, Alberto Stefano Tagliafico
{"title":"Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients.","authors":"Federico Gatto, Angelo Milioto, Giuliana Corica, Federica Nista, Claudia Campana, Anna Arecco, Lorenzo Mattioli, Lorenzo Belluscio, Bianca Bignotti, Diego Ferone, Alberto Stefano Tagliafico","doi":"10.1007/s11102-024-01422-y","DOIUrl":"https://doi.org/10.1007/s11102-024-01422-y","url":null,"abstract":"<p><strong>Purpose: </strong>The impact of GH/IGF-1 levels on skeletal muscle in acromegaly is still controversial. Temporal (TMT) and masseter muscle (MMT) thickness has been recently demonstrated as a reliable measure of muscle mass. We aimed to investigate the relationship between TMT, MMT and clinical/biochemical characteristics in patients with acromegaly.</p><p><strong>Methods: </strong>Single center retrospective longitudinal study including 69 patients with at least one available brain/sella turcica MRI and matched clinical data. TMT, MMT, and muscle fatty infiltration (modified Goutallier score) were evaluated in all patients at baseline (first available MRI) and over time (182 MRIs analyzed).</p><p><strong>Results: </strong>At baseline, both TMT and MMT were higher in males than females (p = 0.001 and p = 0.016, respectively). TMT and MMT were positively associated (β 0.508, p < 0.001), and they were positively correlated with IGF-1 xULN (TMT, p = 0.047; MMT, p = 0.001). MMT had a positive correlation with patients' weight (p = 0.015) and height (p = 0.006). No correlation was found between TMT, MMT and the presence of hypogonadism. Considering all available MRIs, sex and IGF-1 xULN were significant determinants of TMT and MMT at multivariable analysis (female sex: β -0.345/-0.426, p < 0.001; IGF-1 xULN: β 0.257/0.328, p < 0.001). At longitudinal evaluation, uncontrolled patients at baseline showed a significant reduction of MMT over time (p = 0.044). Remarkable fatty infiltration was observed in 34-37% of MRIs; age was the main determinant (temporal muscle: OR 1.665; p = 0.013; masseter muscle: OR 1.793; p = 0.009).</p><p><strong>Conclusion: </strong>Male patients with higher IGF-1 values have thicker temporal and masseter muscles, suggesting that sex and IGF-1 have a significant impact on muscle mass in acromegaly.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pituitary surgery and COVID. 脑垂体手术和 COVID。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-05 DOI: 10.1007/s11102-024-01423-x
Ameen Farsakh, Sandra Li, Fidel Toomey, Mendel Castle-Kirszbaum, Jeremy Kam, Tony Goldschlager
{"title":"Pituitary surgery and COVID.","authors":"Ameen Farsakh, Sandra Li, Fidel Toomey, Mendel Castle-Kirszbaum, Jeremy Kam, Tony Goldschlager","doi":"10.1007/s11102-024-01423-x","DOIUrl":"https://doi.org/10.1007/s11102-024-01423-x","url":null,"abstract":"<p><p>An effect of the COVID-19 pandemic was the disruption of healthcare systems, especially surgical services provided to the community. Pituitary surgery was especially impacted, given the majority of cases were deemed non-urgent with very few exceptions, and the high risk of viral transmission conferred by the endoscopic endonasal transsphenoidal approach. Patients suffering from pituitary lesions with resultant endocrinopathy or visual symptoms saw their treatment delayed or altered, which had implications on their outcomes and care. This disruption extended to surgical training and the usual functioning of academic units, necessitating changes to curricula and implementation of novel methods of progressing surgical education. This review will explore the effect of the COVID pandemic on pituitary surgery, the experiences of various surgeons as well as the adaptations implemented on the frontlines. The lessons learned from the experience of the pandemic may assist specialists in gleaning insights regarding the care of patients in the future.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of medical therapy for hormone-secreting Pituitary tumors on bone. 激素分泌型垂体瘤的药物治疗对骨骼的影响。
IF 3.3 2区 医学
Pituitary Pub Date : 2024-07-05 DOI: 10.1007/s11102-024-01421-z
Pamela U Freda
{"title":"Impact of medical therapy for hormone-secreting Pituitary tumors on bone.","authors":"Pamela U Freda","doi":"10.1007/s11102-024-01421-z","DOIUrl":"https://doi.org/10.1007/s11102-024-01421-z","url":null,"abstract":"<p><strong>Purpose: </strong>Bone health is often impaired in patients with hormone-secreting pituitary tumors. Since medical therapy is central to their care, understanding how its use impacts on this is highly important.</p><p><strong>Methods: </strong>This review summarizes a systemmatic review of the literature on the effects of medical therapies for hormone-secreting pituitary tumors on bone.</p><p><strong>Results: </strong>In acromegaly, medical therapy lowers bone turnover marker (BTM) levels, consistent with correction of the high bone turnover of active disease, and overall, areal bone mineral density (aBMD) does not change or increases. Somatostatin-receptor ligand (SRL) and pegvisomant-treated acromegaly patients have persistently reduced volumetric BMD and microarchitectural abnormalities of the peripheral skeleton, deficits that are similar to those in surgically-treated patients. Fracture risk remains elevated in medically-treated acromegaly patients but in conjunction with biochemical control the risk is lessened. Treatment of prolactin-secreting tumors with dopamine agonists is associated with improvements in aBMD, but this does not always fully normalize despite effective medical treatment of the prolactinoma. In one cross-sectional study, prolactinoma patients had lower total volumetric BMD and impaired microarchitecture suggesting that bone microstructure does not fully normalize despite dopamine agonist therapy. Cross-sectional studies show a high rate of VF in patients with prolactin-secreting tumors that is lowered on cabergoline therapy, but still the fracture rate of men and postmenopausal women is higher than that of controls in some studies. Studies on the effects of modern-day medical therapy for Cushing's disease on bone are lacking.</p><p><strong>Conclusion: </strong>More research is needed on the effectsof medical therapies for hormone secreting pituitary tumors on bone health.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信